Analysts Set TG Therapeutics, Inc. (NASDAQ:TGTX) PT at $53.33

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned an average rating of “Moderate Buy” from the nine research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $53.3333.

TGTX has been the subject of a number of analyst reports. Weiss Ratings upgraded TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Bank of America lifted their target price on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. HC Wainwright upped their price target on TG Therapeutics from $70.00 to $77.00 and gave the stock a “buy” rating in a report on Monday. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $83.00 price target on shares of TG Therapeutics in a report on Monday, June 22nd.

Institutional Trading of TG Therapeutics

Institutional investors have recently made changes to their positions in the company. Danske Bank A S bought a new position in shares of TG Therapeutics during the third quarter valued at about $25,000. EverSource Wealth Advisors LLC grew its position in TG Therapeutics by 51.9% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 365 shares in the last quarter. Hantz Financial Services Inc. grew its position in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC increased its stake in TG Therapeutics by 172.4% in the 4th quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in TG Therapeutics in the 4th quarter valued at about $52,000. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Stock Down 2.6%

TG Therapeutics stock opened at $54.93 on Tuesday. TG Therapeutics has a 1-year low of $25.28 and a 1-year high of $59.30. The firm has a market capitalization of $8.41 billion, a price-to-earnings ratio of 19.21, a price-to-earnings-growth ratio of 1.41 and a beta of 1.60. The firm’s fifty day moving average price is $47.51 and its two-hundred day moving average price is $37.03. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a return on equity of 88.73% and a net margin of 65.95%.The business had revenue of $204.92 million for the quarter, compared to the consensus estimate of $200.33 million. During the same period in the previous year, the firm earned $0.03 earnings per share. The company’s revenue was up 69.5% on a year-over-year basis. On average, equities research analysts predict that TG Therapeutics will post 1.46 earnings per share for the current fiscal year.

TG Therapeutics News Roundup

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating on TG Therapeutics and maintained a $77 price target, signaling confidence in the company’s growth potential. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: H.C. Wainwright raised its longer-term earnings forecasts for FY2028, FY2029, and FY2030, suggesting expectations for improving profitability over time.
• Neutral Sentiment: Another recent report noted analysts are split on TG Therapeutics, reinforcing that sentiment around the name remains mixed rather than universally bullish. Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX)
• Neutral Sentiment: H.C. Wainwright also trimmed some near-term EPS estimates for Q2, Q3, and FY2026, indicating expectations for softer earnings in the short run even though the long-term outlook improved.
• Negative Sentiment: Bank of America Securities kept a Sell rating on TG Therapeutics, adding a bearish counterpoint that may weigh on investor sentiment. Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX)

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.